Pfizer and BioNTech on Friday announced that they have applied for emergency authorization for its COVID-19 vaccine.
The application comes just two days after the companies submitted final efficacy data on its vaccine, showing it to be 95 percent effective “against COVID-19 beginning 28 days faster the first dose.”
The companies said that they could potentially receive authorization for the vaccine in high-risk populations by the end of December.
In addition to the U.S., the companies have already begun submissions in Europe and the U.K., and intends to submit more “in the coming days.”
This developing report will be updated.
